...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus
【24h】

Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus

机译：用重组金丝雀痘病毒载体的疫苗共表达基因编码非洲马瘟病毒外衣壳蛋白对马进行保护性免疫

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We describe the development and preliminary characterization of a recombinant canarypox virus vectored (ALVAC (R))vaccine for protective immunization of equids against African horsesickness virus (AHSV) infection. Horses (n = 8) immunized with either of two concentrations of recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) developed variable titres (<10-80) of virus-specific neutralizing antibodies and were completely resistant to challenge infection with a virulent strain of AHSV-4. In contrast, a horse immunized with a commercial recombinant canarypox virus vectored vaccine expressing the haemagglutinin genes of two equine influenza H3N8 viruses was seronegative to AHSV and following infection with virulent AHSV-4 developed pyrexia, thrombocytopenia and marked oedema of the supraorbital fossae typical of the "clikkop" or cardiac form of African horse sickness. AHSV was detected by virus isolation and quantitative reverse transcriptase polymerase chain reaction in the blood of the control horse from 8 days onwards after challenge infection whereas AHSV was not detected at any time in the blood of the ALVAC-AHSV vaccinated horses. The control horse seroconverted to AHSV by 2 weeks after challenge infection as determined by both virus neutralization and ELISA assays, whereas six of eight of the ALVAC-AHSV vaccinated horses did not seroconvert by either assay following challenge infection with virulent AHSV-4. These data confirm that the ALVAC-AHSV vaccine will be useful for the protective immunization of equids against African horse sickness, and avoids many of the problems inherent to live-attenuated AHSV vaccines.
机译：我们描述了重组金丝雀痘病毒载体（ALVAC（R））疫苗的开发和初步鉴定，该疫苗用于对非洲马蹄疫病毒（AHSV）感染的马进行保护性免疫。用共表达编码AHSV血清型4（AHSV-4）的外衣壳蛋白（VP2和VP5）的合成基因的两种浓度的重组金丝雀痘病毒载体（ALVAC-AHSV）中的任一种免疫的马（n = 8）出现了可变滴度（ <10-80）的病毒特异性中和抗体，并完全抵抗AHSV-4强毒株的攻击感染。相反，用表达两种马H3N8流感病毒血凝素基因的商业重组金丝雀痘病毒载体疫苗免疫的马对AHSV呈阴性，并在被强毒AHSV-4感染后发展为发热，血小板减少和眶上窝典型的明显水肿非洲马sick的“ clikkop”或心脏形式。从攻击感染后第8天开始，通过病毒分离和定量逆转录酶聚合酶链反应在对照组马的血液中检测到AHSV，而在接种ALVAC-AHSV的马的血液中始终未检测到AHSV。通过病毒中和和ELISA分析确定，对照马在攻击感染后2周血清转化为AHSV，而在ALVAC-AHSV疫苗接种的八匹马中，有六只在强力AHSV-4攻击感染后未通过血清分析转化为AHSV。这些数据证实，ALVAC-AHSV疫苗将可用于针对非洲马匹疾病的马匹的保护性免疫接种，并避免了减毒AHSV活疫苗固有的许多问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号